In this episode, Dr. Paul Sieber and Ashley Rentisky, PA-C, are joined by Dr. Evan Goldfischer, past president of LUGPA, to address the underutilization of germline and tumor (somatic) testing somatic testing in prostate cancer management. They will discuss challenges practices face in integrating genetic testing into clinical workflows and offer strategies for overcoming barriers.

Tune in for expert insights and actionable advice that can transform prostate cancer care!

Send a text

Dr. Paul Sieber and co-host Ashleigh Renitsky, Oncology PA, are joined by Dr. Morris from Urology Associates of Nashville to discuss how clinical guidelines have driven increased awareness of germline and somatic mutations in prostate cancer. They discuss how germline and somatic testing can help personalize treatment strategies and share real world case studies. The conversation also encourages the need for continued education in this rapidly advancing field and adoption of genetic testing in urology.

Send a text

In the second episode of our miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA, will break down the different types of genetic and molecular tests—including gene expression, germline, somatic, and circulating tumor DNA tests—discuss which patients qualify for each, and explore how to implement streamlined testing protocols in their practice to ensure their patients are receiving the standard of care. They’ll also cover the critical role of genetic counselors in helping patients understand their test results and make informed treatment decisions.

Whether you're a provider, nurse practitioner, or physician assistant, this podcast will provide valuable insights to help integrate genetic testing into your practice.

Learn more at Prolaris.com

Send a text

The Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.

Episode #1 - Genetic testing basics
The first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors.

Send a text

In this conversation, Dr. Tim Richardson from Wichita Urology and Dr. Ben Lowentritt from Chesapeake Urology discuss the integration and utilization of Advanced Practice Providers (APPs) in urology practices, particularly within advanced prostate cancer (APC) clinics. Dr. Lowentritt explains the benefits of using APPs to address physician shortages, increase efficiency, and more.

Send a text

Dr. Tim Richardson from Wichita Urology and Dr. Jonathan Henderson from Arkansas Urology discuss the use and benefits of Prolaris testing in prostate cancer management. Dr. Henderson elaborates on how Prolaris aids in decision-making for his prostate cancer patients, highlighting its role in reducing overtreatment and undertreatment.

Send a text

Dr. Tim Richardson from Wichita Urology interviews Dr. Scott Sellinger, the current president - elect of the Large Urology Group Practice Association (LUGPA). They discuss LUGPA's history, current status, and future goals. Initially founded to support large independent urology practices, LUGPA now includes any independent urology practice. Dr. Sellinger also highlights the challenges facing independent urology practices.

*Episode was filmed 11/23

Send a text

In this episode of The Modern Urologist, Dr. Mark Edney is joined by Dr. Paul Sieber, a urologist from Lancaster, Pennsylvania, to discuss the use of genetic testing in the diagnosis and treatment of prostate cancer. Dr. Sieber emphasizes the importance of hereditary cancer testing, as well as tissue-based biomarkers like Prolaris®, in determining the best treatment plans for this prostate cancer patients.

Send a text